Comprehensive Clinical Guide: Pterygium Excision with Conjunctival Autograft

1. Introduction and Overview

A pterygium is a fibrovascular, wedge-shaped growth of the bulbar conjunctiva that extends onto the cornea. While often considered a benign condition, it can cause significant ocular irritation, cosmetic dissatisfaction, astigmatism, and, in advanced cases, visual impairment due to corneal involvement.

The gold standard for the surgical management of primary and recurrent pterygia is Pterygium Excision with Conjunctival Autograft (P-CAG). This procedure involves the removal of the pterygium tissue followed by the transplantation of healthy conjunctival tissue from the superior or inferior bulbar conjunctiva to the bare scleral bed created by the excision. The primary goal of this technique is to minimize recurrence rates, which historically plagued simpler excision methods, by restoring the normal ocular surface anatomy and inhibiting the fibrovascular proliferation associated with pterygium recurrence.

2. Technical Specifications and Mechanisms

The mechanism of P-CAG relies on the "barrier effect." By transplanting healthy, non-inflamed conjunctival tissue, the surgeon effectively covers the exposed sclera (the bare sclera technique is known for high recurrence due to unchecked inflammatory cell migration).

The Pathophysiological Rationale

• Limbal Barrier Restoration: The conjunctival graft carries limbal stem cells, which help maintain the integrity of the corneal epithelium and prevent the conjunctivalization of the cornea.
• Reduced Inflammation: The graft acts as a physical barrier that prevents the migration of fibroblasts and inflammatory mediators from the surrounding conjunctiva into the excision site.
• Mechanical Stability: The graft provides a smooth, physiologic surface that promotes rapid re-epithelialization and reduces the stimulus for scar tissue formation.

Comparison of Excision Techniques

3. Clinical Indications and Usage

Pterygium excision is generally reserved for symptomatic patients or those with progressive pathology.

Primary Indications

1. Visual Disturbance: Induced astigmatism or direct encroachment into the visual axis.
2. Ocular Irritation: Chronic redness, foreign body sensation, burning, or epiphora (tearing) that is unresponsive to conservative management (lubricants, vasoconstrictors).
3. Cosmetic Concern: Significant aesthetic impact affecting patient self-esteem.
4. Recurrent Inflammation: Frequent episodes of pterygium-related conjunctivitis.

Contraindications

• Active Ocular Surface Disease: Severe dry eye syndrome or autoimmune conditions (e.g., Ocular Cicatricial Pemphigoid) where conjunctival harvesting might exacerbate the underlying disease.
• Glaucoma Surgery Considerations: Patients who may require future trabeculectomy should avoid harvesting conjunctiva from the superior bulbar area if possible, to preserve the conjunctival "real estate."
• Infection: Active bacterial, viral, or fungal conjunctivitis or keratitis.

4. Pre-Operative Preparation

Success begins with meticulous planning.
* Ocular Surface Optimization: Use of preservative-free artificial tears and, if necessary, short-term topical steroids to reduce inflammation prior to surgery.
* Patient Counseling: Discussion regarding the risk of recurrence, the potential for post-operative discomfort, and the nature of the graft.
* Anesthesia: Typically performed under topical anesthesia (e.g., tetracaine/proparacaine) supplemented with sub-Tenon’s or sub-conjunctival lidocaine injection.
* Antisepsis: Povidone-iodine 5% solution applied to the ocular surface and periocular skin.

5. The Procedure: Step-by-Step

The procedure is generally performed in an outpatient setting.

Step 1: Excision

The pterygium head is separated from the cornea using a crescent blade or a Beaver blade. The body of the pterygium is dissected from the underlying sclera, ensuring that all fibrovascular tissue is removed. The goal is to create a smooth, clean scleral bed.

Step 2: Hemostasis

Meticulous hemostasis is performed using cautery to prevent subconjunctival hemorrhage, which can increase the risk of recurrence.

Step 3: Harvesting the Autograft

A piece of healthy conjunctiva (usually from the superior bulbar region) is measured and harvested. It is essential to include a thin layer of Tenon’s fascia to ensure graft viability, though excessive Tenon’s tissue should be trimmed to prevent post-operative thickening.

Step 4: Graft Placement and Fixation

The graft is transferred to the bare scleral bed. It is oriented with the epithelial side up (limbal edge towards the cornea). Fixation is achieved via:
* Sutures: 8-0 or 10-0 absorbable sutures (e.g., Vicryl or Nylon).
* Fibrin Glue: A common modern alternative that reduces surgical time and post-operative discomfort by eliminating suture-related irritation.

6. Post-Operative Recovery Protocol

Patients are typically patched for 24 hours.

• Medication Regimen:
  • Antibiotics: Topical fluoroquinolones (e.g., moxifloxacin) four times daily for 1-2 weeks.
  • Steroids: Topical corticosteroids (e.g., prednisolone acetate or loteprednol) are tapered over 4-6 weeks to control inflammation.
  • Lubricants: Preservative-free artificial tears are essential for the first 3 months.
• Follow-up Schedule: Day 1, Week 1, Month 1, and Month 3.
• Activities: Avoid swimming, rubbing the eye, and heavy lifting for at least two weeks. Protective eyewear is recommended for outdoor activities to reduce UV exposure.

7. Potential Complications

While highly successful, P-CAG is a surgical procedure and carries inherent risks:
* Graft Retraction/Dehiscence: The graft may pull away from the edges.
* Graft Edema: Common in the first week; usually self-limiting.
* Infection: Rare, but requires immediate intervention.
* Scleral Thinning/Necrosis: Associated with excessive cautery or use of mitomycin-C (if adjunct therapy is utilized).
* Granuloma Formation: Usually at the suture site; may require excision.
* Recurrence: Although low, recurrence remains the primary long-term challenge.

8. Alternative Treatments

• Amniotic Membrane Transplantation (AMT): Used for large or recurrent pterygia where there is insufficient healthy conjunctiva to harvest.
• Mitomycin-C (MMC): An anti-metabolite applied during surgery to inhibit fibroblastic activity. While effective, it carries risks of scleral melting and should be used with extreme caution.
• Simple Excision: No longer recommended due to unacceptably high recurrence rates.

9. Frequently Asked Questions (FAQ)

1. Is Pterygium Excision with Conjunctival Autograft painful?

The surgery itself is painless due to local anesthesia. Post-operatively, patients typically experience a "gritty" or foreign body sensation for 3-7 days, which is managed effectively with lubricants and prescribed pain relief.

2. How long does the procedure take?

Typically, the procedure lasts between 20 to 45 minutes per eye, depending on the complexity of the pterygium.

3. What is the success rate of this surgery?

When performed with a conjunctival autograft, the success rate in preventing recurrence is generally 95% or higher.

4. Will I need stitches?

Modern techniques often utilize fibrin glue, which eliminates the need for sutures. If sutures are used, they are typically dissolvable, but some surgeons prefer non-dissolvable sutures that are removed at the one-week follow-up.

5. When can I return to work?

Most patients return to light work within 2-3 days, provided they are not in a dusty or contaminated environment.

6. Can a pterygium come back after surgery?

Yes, there is a small chance of recurrence (usually <5%). Risk factors for recurrence include younger age, high UV exposure, and excessive inflammation post-operatively.

7. Does the donor site (where the graft was taken) heal?

Yes, the donor site in the superior conjunctiva heals quickly (within 1-2 weeks) and typically leaves no long-term aesthetic or functional deficit.

8. How long do I need to use eye drops?

Steroid drops are usually tapered over 4-8 weeks, while artificial tears may be recommended for 3 months to support ocular surface healing.

9. Can I wear contact lenses after surgery?

It is recommended to wait at least 4-6 weeks post-surgery before resuming contact lens wear, pending confirmation of surface healing by your ophthalmologist.

10. Why is UV protection important after surgery?

UV radiation is the primary environmental trigger for pterygium formation. Consistent use of UV-blocking sunglasses is critical to prevent the recurrence of the growth.

10. Conclusion

Pterygium Excision with Conjunctival Autograft represents the standard of care for ocular surface reconstruction following pterygium removal. By prioritizing the health of the ocular surface and utilizing autologous tissue, surgeons can achieve excellent functional and cosmetic outcomes. Proper patient selection, meticulous surgical technique, and strict adherence to the post-operative regimen are the pillars of success in managing this common but often debilitating condition.